|
EP0325199B1
(en)
|
1988-01-19 |
1993-10-27 |
Takeda Chemical Industries, Ltd. |
Fumagillin as angiostatic agent
|
|
KR0141692B1
(ko)
|
1988-09-01 |
1998-06-01 |
우메모또 요시마사 |
맥관 형성 억제제
|
|
PT1537878E
(pt)
|
2002-07-03 |
2010-11-18 |
Ono Pharmaceutical Co |
Composições de imunopotenciação
|
|
US9707302B2
(en)
*
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
US20090275619A1
(en)
|
2006-04-03 |
2009-11-05 |
BOUERES Julia |
Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
|
|
EA016079B1
(ru)
|
2007-01-10 |
2012-01-30 |
Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа |
Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
|
|
KR101586617B1
(ko)
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
|
|
CA2705417A1
(en)
|
2007-11-12 |
2009-05-22 |
Bipar Sciences, Inc. |
Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
|
|
JP2011503111A
(ja)
|
2007-11-12 |
2011-01-27 |
バイパー サイエンシズ，インコーポレイティド |
Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
|
|
CN101959429B
(zh)
|
2008-01-08 |
2014-09-10 |
阿克塞利亚制药公司 |
抗微生物肽系统的激动剂
|
|
NZ586675A
(en)
|
2008-01-08 |
2012-04-27 |
Merck Sharp & Dohme |
Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
|
|
EP4209510B1
(en)
|
2008-12-09 |
2024-01-31 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
KR20110113648A
(ko)
|
2009-02-04 |
2011-10-17 |
바이파 사이언스 인코포레이티드 |
Ｐａｒｐ 억제제와 함께 성장인자 억제제를 사용한 폐암의 치료
|
|
NO2504364T3
(enExample)
|
2009-11-24 |
2018-01-06 |
|
|
|
WO2011153383A1
(en)
|
2010-06-04 |
2011-12-08 |
Bipar Science, Inc. |
Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
|
|
DK3012329T3
(da)
|
2010-06-18 |
2017-11-20 |
Myriad Genetics Inc |
Fremgangsmåder og materialer til at vurdere tab af heterozygositet
|
|
DK2609216T3
(en)
|
2010-08-24 |
2016-09-12 |
Dana Farber Cancer Inst Inc |
Methods to predict anti-cancer response
|
|
CA2742342A1
(en)
|
2011-02-12 |
2012-08-12 |
Baylor Research Institute |
Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
|
|
US9624298B2
(en)
|
2011-11-28 |
2017-04-18 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
|
AU2013273466B2
(en)
|
2012-06-07 |
2018-11-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
|
|
DK2928865T3
(en)
|
2012-12-07 |
2018-06-18 |
Merck Sharp & Dohme |
BIOCATALYTIC TRANSAMINATION PROCEDURE
|
|
US9580407B2
(en)
|
2012-12-07 |
2017-02-28 |
Merck Sharp & Dohme Corp. |
Regioselective N-2 arylation of indazoles
|
|
WO2014138101A1
(en)
|
2013-03-04 |
2014-09-12 |
Board Of Regents, The University Of Texas System |
Gene signature to predict homologous recombination (hr) deficient cancer
|
|
AR095363A1
(es)
|
2013-03-15 |
2015-10-14 |
Genentech Inc |
Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
|
|
JP6742903B2
(ja)
|
2013-05-02 |
2020-08-19 |
アナプティスバイオ インコーポレイティッド |
プログラム死−１（ｐｄ−１）に対する抗体
|
|
WO2015086473A1
(en)
|
2013-12-09 |
2015-06-18 |
Institut Curie |
Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
|
|
US20180163271A1
(en)
|
2014-01-16 |
2018-06-14 |
Clovis Oncology, Inc. |
Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity
|
|
AU2015210886A1
(en)
*
|
2014-01-29 |
2016-09-01 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
|
EP3148336B1
(en)
|
2014-05-28 |
2019-10-02 |
Eisai R&D Management Co., Ltd. |
Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
|
|
US20150344968A1
(en)
|
2014-05-30 |
2015-12-03 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Methods for determining parp inhibitor and platinum resistance in cancer therapy
|
|
EP3230472A4
(en)
|
2014-12-08 |
2018-06-13 |
Myriad Genetics, Inc. |
Methods and materials for predicting response to niraparib
|
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
EP3277321B1
(en)
|
2015-04-01 |
2024-08-14 |
AnaptysBio, Inc. |
Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
|
|
JP2018514550A
(ja)
|
2015-04-28 |
2018-06-07 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
|
|
HK1251474A1
(zh)
|
2015-06-08 |
2019-02-01 |
豪夫迈‧罗氏有限公司 |
使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
|
|
AU2016281622C1
(en)
|
2015-06-25 |
2021-11-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
PL3337467T3
(pl)
|
2015-08-20 |
2021-06-14 |
Ipsen Biopharm Ltd. |
Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu
|
|
WO2017075091A1
(en)
|
2015-10-26 |
2017-05-04 |
Medivation Technologies, Inc. |
Treatment of small cell lung cancer with a parp inhibitor
|
|
JP6865762B2
(ja)
|
2016-02-15 |
2021-04-28 |
アストラゼネカ アクチボラグ |
セジラニブの一定間欠投与を含む方法
|
|
FI3478286T3
(fi)
|
2016-06-29 |
2024-03-14 |
Tesaro Inc |
Menetelmiä munasarjasyövän hoitamiseksi
|
|
WO2018059437A1
(en)
|
2016-09-27 |
2018-04-05 |
Beigene, Ltd. |
Treatment cancers using combination comprising parp inhibitors
|
|
SG11201903867YA
(en)
|
2016-11-01 |
2019-05-30 |
Anaptysbio Inc |
Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
|
|
EP3666794A1
(en)
|
2016-11-01 |
2020-06-17 |
AnaptysBio, Inc. |
Antibodies directed against programmed death- 1 (pd-1)
|
|
EP3565844B8
(en)
|
2017-01-09 |
2023-04-12 |
Tesaro, Inc. |
Methods of treating cancer with anti-pd-1 antibodies
|
|
JP7118073B2
(ja)
|
2017-01-09 |
2022-08-15 |
テサロ， インコーポレイテッド |
抗ｔｉｍ－３抗体を用いてがんを処置する方法
|
|
BR112019020191A2
(pt)
|
2017-03-27 |
2020-04-22 |
Tesaro Inc |
formulações de niraparib
|
|
EA201992177A1
(ru)
|
2017-03-27 |
2020-02-25 |
Тесаро, Инк. |
Композиции на основе нирапариба
|
|
CN110753684A
(zh)
|
2017-04-24 |
2020-02-04 |
特沙诺有限公司 |
尼拉帕利的制造方法
|
|
SG11201909395TA
(en)
|
2017-04-27 |
2019-11-28 |
Tesaro Inc |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
TW202444417A
(zh)
|
2017-05-09 |
2024-11-16 |
美商提薩羅有限公司 |
治療癌症的組合療法
|
|
EP3624850A1
(en)
|
2017-05-18 |
2020-03-25 |
Tesaro, Inc. |
Combination therapies for treating cancer
|
|
WO2019005762A1
(en)
|
2017-06-26 |
2019-01-03 |
Abbvie Inc. |
TREATMENT OF NON-SMALL CELL LUNG CANCER
|
|
AU2018341479B2
(en)
|
2017-09-26 |
2022-02-17 |
Tesaro, Inc. |
Niraparib formulations
|
|
KR20200086664A
(ko)
|
2017-09-30 |
2020-07-17 |
테사로, 인코포레이티드 |
암을 치료하기 위한 조합 요법
|
|
MA50618A
(fr)
|
2017-10-06 |
2020-08-12 |
Tesaro Inc |
Polyrhérapies et leurs utilisations
|
|
CA3087060A1
(en)
|
2017-12-27 |
2019-07-04 |
Tesaro, Inc. |
Methods of treating cancer
|
|
EP3749352A1
(en)
|
2018-02-05 |
2020-12-16 |
Tesaro Inc. |
Pediatric niraparib formulations and pediatric treatment methods
|
|
EA201992594A1
(ru)
|
2018-03-26 |
2020-03-20 |
Тесаро, Инк. |
Комбинированные терапии для лечения рака
|
|
US11970530B2
(en)
|
2020-08-13 |
2024-04-30 |
Astrazeneca Ab |
Methods of treating homologous recombination deficient cancer
|